BioSpace News Archive

Initiates Clinical Proof of Concept Study for NFX-179 Gel for the Mitigation of Cutaneous Neurofibromatosis Type-1

Boston Microfluidics, a developer of simple, intuitive blood collection devices, announced that it has appointed Linh Hoang, MD, PhD, as its new Chief Executive Officer.

Integrity Bio announces the validation of its second fill/finish manufacturing line.

Titan Medical Inc. announces that it has entered into a settlement agreement with Naglreiter Consulting, LLC, d/b/a Naglreiter MDDO to settle claims in the lawsuit styled Naglreiter Consulting LLC, d/b/a Naglreiter MDDO v. Titan Medical Inc. pending in the United States District Court for the Southern District of Florida.

Genprex, Inc. (“Genprex” or the “Company”) (Nasdaq: GNPX ), a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes, today announced that it is scheduled to join the U.S. broad-market Russell 3000 Index when FTSE Russell, a leading global index provider, reconstitutes its 2020 indices after the markets clo

Mercy Clinic announced it has launched rapid COVID-19 testing, together with CVS Health at its South Fort Worth clinic.

Nella™ NuSpec™, VuSleeve® and VuLight® provide new products complimenting Lupin’s Specialty offering

TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that Michael S. Weiss, the Company’s Executive Chairman and Chief Executive Officer, will participate in a fireside chat during the Gladman Sachs 41 st Annual Healthcare Conference, being held virtually. The fireside chat is scheduled to take place on Thursday, June 11, 2020 at 4:40 PM ET. A live webcast of this presentation will be available on the Events page, located within the Investors &am

Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that its Senior Vice President and Chief Scientific Officer, Oreola Donini, PhD, will deliver a presenta

Forma Therapeutics Announces Phase I Clinical Data for Investigational Agent FT-4202 in Sickle Cell Disease to be Presented at the Virtual Edition of the 25 th European Hematology Association Annual Congress Poster presentation to highlight the tolerability, pharmacokinetics and pharmacodynamics of FT-4202 in Phase I clinical trials of single and multiple ascending dose cohorts of healthy subjects, Phase I clinical trials of single dose of SCD patients